ResMed (RMD) is Downgraded by Piper Jaffray to Neutral

ResMed (RMD) was Downgraded by Piper Jaffray to ” Neutral”. Earlier the firm had a rating of “Overweight ” on the company shares. Piper Jaffray advised their investors in a research report released on Apr 27, 2016.

Many Wall Street Analysts have commented on ResMed. Barclays Resumed ResMed on Apr 7, 2016 to “Underweight”, Price Target of the shares are set at $55.

On the company’s financial health, ResMed reported $0.68 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.69. The company had revenue of $453.88 million for the quarter, compared to analysts expectations of $455.94 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.65 EPS.

ResMed opened for trading at $60.43 and hit $60.73 on the upside on Friday, eventually ending the session at $60.72, with a gain of 0.46% or 0.28 points. The heightened volatility saw the trading volume jump to 9,50,387 shares. Company has a market cap of $8,503 M.

In a different news, on Apr 19, 2016, Michael J. Farrell (Chief Executive Officer) sold 5,975 shares at $59.34 per share price. According to the SEC, on Apr 12, 2016, Peter C Farrell (director) sold 20,000 shares at $58.62 per share price. On Apr 5, 2016, David Pendarvis (Chief Administrative Officer) sold 6,000 shares at $58.70 per share price, according to the Form-4 filing with the securities and exchange commission.

ResMed Inc. is engaged in the development manufacturing distribution and marketing of medical products for the diagnosis treatment and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders including airflow generators diagnostic products mask systems headgear and other accessories. It produces continuous positive airway pressure variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape AirSense 10 Elite AirSense 10 CPAP S9 VPAP S S9 VPAP ST S9 VPAP Adapt S9 VPAP ST-A S9 VPAP COPD and AirCurve 10 V Auto among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX Swift FX for Her Mirage FX for Her Pixi Pediatric Mask Quattro FX for Her Swift FX Bella Swift FX Nano AirFit N10 and Apnealink Air.


Leave a Reply

ResMed - Is it time to Sell?

Top Brokerage Firms are advising their investors on ResMed. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.